Holen Sie sich die Stockscreener-App
18.02
4.05%
-0.76
Handel nachbörslich:
18.00
-0.02
-0.11%
Schlusskurs vom Vortag:
$18.78
Offen:
$18.61
24-Stunden-Volumen:
1.07M
Relative Volume:
0.70
Marktkapitalisierung:
$1.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-230.32M
KGV:
-5.1108
EPS:
-3.5259
Netto-Cashflow:
$-196.04M
1W Leistung:
-3.12%
1M Leistung:
+5.20%
6M Leistung:
+82.20%
1J Leistung:
-50.99%
1-Tages-Spanne:
$17.87
$19.02
1-Wochen-Bereich:
$17.84
$19.73
52-Wochen-Spanne:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.02 | 1.35B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Hochstufung | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | Herabstufung | Goldman | Neutral → Sell |
| 2026-01-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-11-03 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-09-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-09-30 | Herabstufung | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
H.C. Wainwright reiterates Moonlake stock rating on HS potential By Investing.com - Investing.com Australia
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention - TipRanks
Insider Sell: CEO Santos da Silva Jorge Sells 150,000 Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
MoonLake Immunotherapeutics Chief Executive Officer Sold Shares Worth Over $2.7M - TradingView — Track All Markets
MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares - Stock Titan
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics - TipRanks
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - AOL.com
The Technical Signals Behind (MLTX) That Institutions Follow - Stock Traders Daily
Pre-planned MoonLake (NASDAQ: MLTX) CFO share sale totals 87,795 - Stock Titan
MoonLake Immunotherapeutics (NASDAQ: MLTX) files Form 144 to report Class A resale intent - Stock Titan
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - MSN
What is the Moat Score of MoonLake Immunotherapeutics2026 Recap & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
MLTX (NASDAQ: MLTX) Form 144 shows proposed 150,000-share resale via UBS - Stock Titan
Insmed Drug Misses Primary Goal, Program Axed - Sahm
Weekly Recap: Does MoonLake Immunotherapeutics have declining or rising EPSChart Signals & Free Reliable Trade Execution Plans - baoquankhu1.vn
MoonLake says lead drug shows durable response, eyes FDA filing - MSN
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value - TipRanks
BVF's departure from MoonLake suggests a shift towards high-beta rebalancing as institutions remain divided in their perspectives - Bitget
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - The Motley Fool
MLTX SEC FilingsMoonLake Immunotherapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
How MoonLake’s Phase 3 Sonelokimab HiSCR75 Data in HS Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.st
MoonLake Immunotherapeutics (MLTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa - Yahoo Finance
Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment - TipRanks
Bvf Partners P/Il Sells 3,750,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
BVF-linked MoonLake (MLTX) holder trims stake by 3.75M shares - Stock Titan
MoonLake (MLTX) holder BVF sells shares but keeps 22.3% stake - Stock Titan
Alexa Kimball, MD, MPH, on the Long-Term Efficacy of Sonelokimab and the Evolving HS Landscape - Dermatology Times
MLTX Stock Jumps Overnight: Lead Skin Disease Drug Delivers Strong Phase 3 Gains With Majority Of Patients Improving - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 12.8%Here's Why - MarketBeat
Form 144 | MoonLake Immunotherapeutics(MLTX.US) 10% Stockholder Proposes to Sell 63.49 Million in Common Stocks - Moomoo
Affiliate sale notice: 3,750,000 shares proposed (NASDAQ: MLTX) - Stock Titan
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MoonLake Immunotherapeutics Jumps 9.6% During the Day Amid Positive Developments and Analyst Rating Increases - Bitget
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.7%Here's What Happened - MarketBeat
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook - Investing.com
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After A Premium Price To Book Multiple And Recent Share Moves - simplywall.st
Research Analysts Issue Forecasts for MLTX Q1 Earnings - MarketBeat
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - Stock Traders Daily
What's Going On With MoonLake Stock Monday?MoonLake (NASDAQ:MLTX) - Benzinga
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):